WuXi STA, a subsidiary of WuXi AppTec, opened a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou, China campus. With the opening of the new 30,570 ft2 oligonucleotide plant, WuXi STA officials say they have extended the company’s oligonucleotide development and manufacturing capabilities worldwide, with four large-scale oligonucleotide production lines and more than twenty small- to mid-scale production lines that increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol.

The new 22,260 ft2 peptide plant features three new production lines with reactors that can accommodate up to 1,000 L, increasing WuXi STA’s overall Solid Phase Peptide Synthesis (SPPS) total reactor volume to 6,490 L.

Platform supports oligonucleotides and peptides

The new facility is an essential part of WuXi STA’s comprehensive end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) platform for new modalities, according to Minzhang Chen, PhD, co-CEO of WuXi AppTec and CEO of WuXi STA. The platform supports oligonucleotides and peptides, including novel monomers and linkers, and complex conjugates, from early discovery to development and commercial production at any scale, he notes, adding that with this enhanced manufacturing capacity and over 850 scientists, WuXi STA’s new modality CRDMO platform can better enable global partners as their projects progress to late and commercial stages.

In addition, WuXi STA offers injectable formulation development and manufacturing services, including Lipid NanoParticle technology (LNP), as well as comprehensive analytical and Chemical, Manufacturing, and Controls (CMC) dossier preparation services.

“We are pleased to support our global partners in their efforts to develop new modality therapies for patients in need,” says Chen. “WuXi STA is committed to enabling partners by enhancing our new modality CRDMO platform’s capacity and capability to expedite the development and commercialization of more innovative therapies to benefit patients worldwide.”

WuXi STA has a global network of multiple R&D and manufacturing sites across Asia, North America, and Europe, including a new pharmaceutical manufacturing campus in Middletown, DE that is scheduled to open in 2024.

Last December, WuXi STA signed an agreement making the company the preferred CRDMO partner of Coherent Biopharma.

Previous articleDiscovering the ‘Paradigm Shift’ Associated With Chemoresistance in Acute Myeloid Leukaemia
Next articleBiocon Biologics Receives EU Good Manufacturing Practice Certification